Ratio de rentabilidad sobre activos (ROA)
desde 2018
Cálculo
Moderna Inc., ROA, tendencias a largo plazocálculo
| ROA | = | 100 | × | Utilidad (pérdida) neta1 | ÷ | Activos totales1 | |
|---|---|---|---|---|---|---|---|
| 31 dic 2023 | -25.58% | = | 100 | × | (4,714) | ÷ | 18,426) |
| 31 dic 2022 | 32.34% | = | 100 | × | 8,362) | ÷ | 25,858) |
| 31 dic 2021 | 49.46% | = | 100 | × | 12,202) | ÷ | 24,669) |
| 31 dic 2020 | -10.18% | = | 100 | × | (747) | ÷ | 7,337) |
| 31 dic 2019 | -32.34% | = | 100 | × | (514) | ÷ | 1,589) |
| 31 dic 2018 | -19.61% | = | 100 | × | (385) | ÷ | 1,962) |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31).
1 US$ en millones
Comparación con la competencia
Moderna Inc., ROA, tendencias a largo plazo, comparación con los competidores
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 dic 2023 | -25.58% | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% | 15.92% |
| 31 dic 2022 | 32.34% | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% | 18.30% |
| 31 dic 2021 | 49.46% | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% | 17.44% |
| 31 dic 2020 | -10.18% | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% | 23.07% |
| 31 dic 2019 | -32.34% | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% | 14.15% |
| 31 dic 2018 | -19.61% | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% | 33.57% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31).
Comparativa con el sector industrial: Pharmaceuticals, Biotechnology & Life Sciences
Moderna Inc., ROA, tendencias a largo plazo, en comparación con el sector industrial: pharmaceuticals, biotechnology & life sciences
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| 31 dic 2023 | -25.58% | 7.25% |
| 31 dic 2022 | 32.34% | 10.67% |
| 31 dic 2021 | 49.46% | 10.42% |
| 31 dic 2020 | -10.18% | 5.45% |
| 31 dic 2019 | -32.34% | 9.02% |
| 31 dic 2018 | -19.61% | 8.97% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31).
Comparación con la industria: Health Care
Moderna Inc., ROA, tendencias a largo plazo, en comparación con la industria: health care
| Moderna Inc. | Health Care | |
|---|---|---|
| 31 dic 2023 | -25.58% | 7.19% |
| 31 dic 2022 | 32.34% | 9.66% |
| 31 dic 2021 | 49.46% | 9.46% |
| 31 dic 2020 | -10.18% | 5.81% |
| 31 dic 2019 | -32.34% | 8.32% |
| 31 dic 2018 | -19.61% | 7.90% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31).